Corina Amor Vegas, an HHMI Freeman Hrabowski Scholar at Cold Spring Harbor Laboratory, has engineered a radically new weapon against aging itself: immune cells trained to hunt down and destroy the "zombie cells" that accumulate in our bodies as we grow older and trigger the inflammation, frailty, and cognitive decline we associate with time's passage.
The cells in question—senescent cells—exist in a biological limbo. When cells suffer severe damage, they sometimes can't fully recover but aren't quite ready to die, entering a zombie-like state between life and death. In young people with robust immune systems, this is actually protective: it stops damaged cells from turning cancerous. But as we age, our immune defenses weaken, and these senescent cells accumulate, wreaking havoc on our tissues. "Even a small percentage of these cells in tissues can wreak a lot of havoc," Amor Vegas explains. The damage manifests as chronic inflammation, frailty, metabolic decline, and cognitive loss—the familiar symptoms of aging itself.
Researchers have been testing small-molecule drugs to eliminate senescent cells, but these treatments come with significant limitations: they can harm healthy cells too and require repeated dosing over time, which may diminish their effectiveness. Amor Vegas took a different approach, borrowing a strategy from cancer medicine that has transformed blood cancer treatment over the past decade.
CAR-T cell therapy works by genetically engineering a patient's own immune cells—T cells—to recognize and attack cancer. The modification involves attaching a synthetic receptor called a chimeric antigen receptor (CAR) to the T cell's surface, allowing it to bind to specific proteins on tumor cells and multiply to hunt them down over long periods. Amor Vegas realized this same strategy could work for senescent cells, provided she could identify the right protein target.
The answer lay in a surface protein called uPAR, short for urokinase-type plasminogen activator receptor. This protein becomes highly expressed in senescent cells—a distinguishing mark that allows engineered CAR-T cells to recognize and eliminate them while leaving healthy cells largely untouched. When aging mice received the CAR-T treatment, the results were striking: they became physically stronger, and their metabolic function improved measurably.
With this proof of concept in hand, Amor Vegas and her team are now mapping exactly how and where CAR-T cells work in the body. They've discovered the cells are absorbed more effectively in some tissues than others. While they struggle to cross the blood-brain barrier, they succeed remarkably well in the liver. The gut epithelium has emerged as a particularly promising target. As people age, glucose intolerance develops—a hallmark of aging in both animals and humans. Amor Vegas found that CAR-T cells, whether deployed preventively or to address existing dysfunction, improved gut function, reduced inflammation, and strengthened the gut's regenerative capacity.
Unlike cancer treatments, which require high doses and can trigger serious side effects like cytokine release syndrome, aging involves far fewer senescent cells to target. This means much lower, potentially far safer doses may be effective. The path to human trials will take time: researchers must identify the precise targets in the human body and fully evaluate any immune interactions. But the potential is compelling—a possible long-term solution to the symptoms of aging itself, delivered by the body's own transformed immune cells.